Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Esperion Therapeutics, Inc. | General Counsel | Common Stock | 184K | $104K | $1.25 | Mar 14, 2024 | Direct |
Esperion Therapeutics, Inc. | General Counsel | Stock Option (right to buy) | 150K | Mar 14, 2024 | Direct | ||
Trillium Therapeutics Inc. | General Counsel | Stock Option (Right to Buy) | 0 | Nov 17, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ESPR | Esperion Therapeutics, Inc. | Mar 14, 2024 | 2 | $0 | 4 | Mar 15, 2024 | General Counsel |
ESPR | Esperion Therapeutics, Inc. | Apr 19, 2023 | 1 | -$1.64K | 4 | Apr 20, 2023 | General Counsel |
ESPR | Esperion Therapeutics, Inc. | Mar 14, 2023 | 2 | $0 | 4 | Mar 15, 2023 | General Counsel |
ESPR | Esperion Therapeutics, Inc. | Jan 18, 2023 | 1 | -$44.4K | 4 | Jan 19, 2023 | General Counsel |
ESPR | Esperion Therapeutics, Inc. | Jun 7, 2022 | 1 | $0 | 4 | Jun 9, 2022 | General Counsel |
ESPR | Esperion Therapeutics, Inc. | Jan 27, 2022 | 2 | $0 | 4 | Jan 28, 2022 | General Counsel |
ESPR | Esperion Therapeutics, Inc. | Jan 1, 2022 | 0 | $0 | 3 | Jan 4, 2022 | General Counsel |
TRIL | Trillium Therapeutics Inc. | Nov 17, 2021 | 1 | $0 | 4 | Nov 19, 2021 | General Counsel |